WO2004050853A3 - Uses of the snorf55 receptor - Google Patents

Uses of the snorf55 receptor Download PDF

Info

Publication number
WO2004050853A3
WO2004050853A3 PCT/US2003/038529 US0338529W WO2004050853A3 WO 2004050853 A3 WO2004050853 A3 WO 2004050853A3 US 0338529 W US0338529 W US 0338529W WO 2004050853 A3 WO2004050853 A3 WO 2004050853A3
Authority
WO
WIPO (PCT)
Prior art keywords
snorf55
receptor
methods
antagonists
mammalian
Prior art date
Application number
PCT/US2003/038529
Other languages
French (fr)
Other versions
WO2004050853A2 (en
Inventor
Roman Artymyshyn
Lilliana Delgado
Pierre J-J Vaysse
Karim Berrada
Kelli E Smith
Christophe Gerald
Original Assignee
Synaptic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synaptic Pharma Corp filed Critical Synaptic Pharma Corp
Priority to AU2003297644A priority Critical patent/AU2003297644A1/en
Publication of WO2004050853A2 publication Critical patent/WO2004050853A2/en
Publication of WO2004050853A3 publication Critical patent/WO2004050853A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

This invention provides methods of treating an abnormality that is linked to the activity of the mammalian SNORF55 receptor, as well as methods of determining binding of compounds to the mammalian SNORF55 receptor, methods of identifying agonists and antagonists of the SNORF55 receptor, and agonists and antagonists so identified.
PCT/US2003/038529 2002-12-04 2003-12-03 Uses of the snorf55 receptor WO2004050853A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003297644A AU2003297644A1 (en) 2002-12-04 2003-12-03 Uses of the snorf55 receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30975302A 2002-12-04 2002-12-04
US10/309,753 2002-12-04

Publications (2)

Publication Number Publication Date
WO2004050853A2 WO2004050853A2 (en) 2004-06-17
WO2004050853A3 true WO2004050853A3 (en) 2005-06-02

Family

ID=32467917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/038529 WO2004050853A2 (en) 2002-12-04 2003-12-03 Uses of the snorf55 receptor

Country Status (2)

Country Link
AU (1) AU2003297644A1 (en)
WO (1) WO2004050853A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022129A1 (en) * 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human g protein-coupled receptors
WO2002057783A2 (en) * 2000-12-22 2002-07-25 Glaxo Group Limited Method of screening for gpr40 ligands

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022129A1 (en) * 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human g protein-coupled receptors
WO2002057783A2 (en) * 2000-12-22 2002-07-25 Glaxo Group Limited Method of screening for gpr40 ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAWZDARGO ET AL.: "A cluster of four novel human G protein-coupled receptor genes occuring in close proximity to CD22 gene on chromosome 19q13.1", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 239, no. 2, 20 October 1997 (1997-10-20), pages 543 - 547, XP002067401 *

Also Published As

Publication number Publication date
AU2003297644A1 (en) 2004-06-23
WO2004050853A2 (en) 2004-06-17
AU2003297644A8 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
TR200100267T2 (en) Substituted anilide compositions and methods.
WO2003104410A3 (en) Enzymes
WO2004087875A3 (en) Nucleic acid-associated proteins
WO2004082621A3 (en) Novel ppar agonists, pharmaceutical compositions and uses thereof
WO2003094848A3 (en) Nucleic acid-associated proteins
WO2003070902A3 (en) Receptors and membrane-associated proteins
WO2004053068A3 (en) Protein modification and maintenance molecules
WO2004060282A3 (en) Uses of the snorf207 receptor
WO2004044165A3 (en) Lipid-associated proteins
WO2004009797A3 (en) Protein modification and maintenance molecules
WO2003063688A3 (en) Protein modification and maintenance molecules
WO2004001008A3 (en) Kinases and phosphatases
WO2003104761A3 (en) Measurement of melanocortin peptides and uses thereof
WO2003076586A3 (en) Nucleic acid-associated proteins
DE60319989D1 (en) DIAZABICYLONONANE AND DECANDERIVATE AND THEIR USE AS OPIOID RECEPTOR LIGANDS
WO2004050853A3 (en) Uses of the snorf55 receptor
WO2004056861A3 (en) Glycoisoforms of adiponectin and uses thereof
WO2004112729A3 (en) Dual function compounds and uses thereof
WO2004003162A3 (en) Enzymes
WO2002076507A3 (en) Uses of opg ligand to modulate immune responses
WO2003083084A3 (en) Protein modification and maintenance molecules
WO2004042022A3 (en) Kinases and phosphatases
WO2003100016A3 (en) Protein modification and maintenance molecules
WO2003083082A3 (en) Enzymes
WO2004022705A3 (en) Neurotransmission-associated proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP